Front Endocrinol (Lausanne) February 2023 PMID 36761202

MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.

Yuejun Zheng, Zilin Wei, Tianhui Wang

Download social card

Mentions

Peak: 3 in Feb 2023

across 4 sources since Jan 2023

Extended reach

83,567

potential audience

Total likes

123

Video views

2,864

Mentions per month

Jan 2023 – May 2025

Where it's discussed

X / Twitter4 posts
News2 articles
Blogs2 articles
YouTube1 videos

AI synopsis

What people are saying

The discussions reflect an overall positive view of MOTS-c, with posts mentioning its potential benefits for diseases related to aging and metabolism, such as diabetes and cardiovascular issues. The tone is analytical and optimistic, with some users quoting the detailed molecular information or emphasizing the importance of further research to translate these findings into therapies.

AgreementModerate agreement

Most discussions recognize the potential of MOTS-c as a promising therapeutic target, with some posts emphasizing its relevance to aging and metabolic health.

InterestModerate interest

Participants show moderate curiosity, often summarizing the research findings and noting its relevance to conditions like diabetes and aging.

EngagementModerate engagement

Posts reference the research details, such as the molecular composition of MOTS-c and its effects, indicating active engagement with scientific concepts.

ImpactModerate impact

The overall tone suggests that the publication could influence future research directions and therapeutic strategies, highlighting its potential significance.

Abstract in brief

MOTSc is a small peptide produced by mitochondria that helps regulate cell function, especially during metabolic stress, by moving to the nucleus and controlling gene expression.
Its levels decrease with age, but it has potential benefits for diseases like diabetes, obesity, aging, cardiovascular issues, and inflammation, mainly by improving glucose metabolism in muscles.
Currently, there are no effective clinical methods to use MOTSc in treatments, but research suggests it could be a promising target for developing new therapies through understanding its molecular mechanisms and combining it with synthetic biology.

Read the full abstract

All mentions

MOTS-c Peptide: Potential Therapeutic Agent for Aging and Metabolic Diseases

MOTS-c is a mitochondrial-derived peptide that regulates cell function during metabolic stress, especially by improving glucose metabolism. It decreases with age and shows promise for treating diseases like diabetes…

VigorousClips · May 10, 2025 2,864 views

Dr. Shashank Joshi

@AskDrShashank · X

RT @agingdoc1: MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation https://t.co/LMklLrr9wU @FrontEndocrinol ht…

Feb 22, 2023 · 1 share · 32,578 followers View post →

Agingdoc

@agingdoc1 · X

MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation https://t.co/LMklLrr9wU @FrontEndocrinol https://t.co/CUENo92seX

Feb 22, 2023 · 8 likes · 1 share · 42,378 followers View post →

Orlando_uy

@Orlando_uy · X

MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation https://t.co/2lcv53ypLU

Feb 22, 2023 · 694 followers View post →

Frontiers - Endocrinology

@FrontEndocrinol · X

Jan 25, 2023 · 5,050 followers View post →